|
|
|
|
Vol. 17, Issue 11, 4686-4697, November 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



,||
Departments of Microbiology and Biomedical Engineering, *Robert M. Berne Cardiovascular Research Center, and ||Mellon Prostate Cancer Research Center, University of Virginia, Charlottesville, VA 22908;
Department of Medicine, University of California at San Diego, San Diego, CA 92103; and
Laboratory for Thrombosis Research, Interdisciplinary Research Center, Katholieke Universiteit, Leuven Campus Kortrijk, 8500 Kortrijk, Belgium
Submitted April 10, 2006;
Revised July 25, 2006;
Accepted August 14, 2006
Monitoring Editor: Richard Hynes
Atherosclerotic plaque develops at sites of disturbed flow. We previously showed that flow activates endothelial cell integrins, which then bind to the subendothelial extracellular matrix (ECM), and, in cells on fibronectin or fibrinogen, trigger nuclear factor-
B activation. Additionally, fibronectin and fibrinogen are deposited into the subendothelial ECM at atherosclerosis-prone sites at early times. We now show that flow activates ECM-specific signals that establish patterns of integrin dominance. Flow induced
2
1 activation in cells on collagen, but not on fibronectin or fibrinogen. Conversely,
5
1 and
v
3 are activated on fibronectin and fibrinogen, but not collagen. Failure of these integrins to be activated on nonpermissive ECM is because of active suppression by the integrins that are ligated. Protein kinase A is activated specifically on collagen and suppresses flow-induced
v
3 activation. Alternatively, protein kinase C
is activated on fibronectin and mediates
2
1 suppression. Thus, integrins actively cross-inhibit through specific kinase pathways. These mechanisms may determine cellular responses to complex extracellular matrices.
This article was published online ahead of print in MBC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E06-04-0289) on August 23, 2006.
Address correspondence to: Martin A. Schwartz (maschwartz{at}virginia.edu)
Abbreviations used: bFGF, basic fibroblast growth factor; BAE, bovine aortic endothelial; BSA, bovine serum albumin; CaMKII, calcium/calmodulin-dependent kinase II; Coll, collagen; Dab-2, disabled-2; eNOS, endothelial nitric-oxide synthase; ECM, extracellular matrix; FBS, fetal bovine serum; FG, fibrinogen; FN, fibronectin; GST, glutathione S-transferase; HA, hemagglutinin; PMA, phorbol 12-myristate 13-acetate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; PI 3-kinase, phosphoinositide 3-kinase; PTB, phosphotyrosine binding domain; PK, protein kinase
This article has been cited by other articles:
![]() |
A. W. Orr, C. Hahn, B. R. Blackman, and M. A. Schwartz p21-Activated Kinase Signaling Regulates Oxidant-Dependent NF-{kappa}B Activation by Flow Circ. Res., September 12, 2008; 103(6): 671 - 679. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Helmke Choosing Sides in Polarized Endothelial Adaptation to Shear Stress Circ. Res., July 18, 2008; 103(2): 122 - 124. [Full Text] [PDF] |
||||
![]() |
W. Koh, R. D. Mahan, and G. E. Davis Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling J. Cell Sci., April 1, 2008; 121(7): 989 - 1001. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Furman, A. L. Sieminski, A. V. Kwiatkowski, D. A. Rubinson, E. Vasile, R. T. Bronson, R. Fassler, and F. B. Gertler Ena/VASP is required for endothelial barrier function in vivo J. Cell Biol., November 19, 2007; 179(4): 761 - 775. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M Agius Complicated atheromatous plaque as integral atherogenesis J. Clin. Pathol., June 1, 2007; 60(6): 589 - 592. [Full Text] [PDF] |
||||